# Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

> **NCT06455748** · NA · RECRUITING · sponsor: **Yongyong MA** · enrollment: 20 (estimated)

## Conditions studied

- Amyloid Light-chain Amyloidosis

## Interventions

- **DRUG:** Daratumumab/daratumumab and hyaluronidase-fihj
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06455748
- **Lead sponsor:** Yongyong MA
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06455748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06455748, "Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06455748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*